UB Paderborn / Katalog / Suche / in CDI

Es ist ein Fehler in der Kommunikation mit einem externen System aufgetreten. Bitte versuchen Sie Ihre letzte Aktion erneut. Sollte der Fehler bestehen bleiben, setzen Sie sich bitte mit dem Informationszentrum der Bibliothek in Verbindung oder versuchen Sie es später erneut.

1 – 25 von 173

Sortiert nach

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

Journal of clinical oncology, 2001-07, Vol.19 (13), p.3210-3218

2001

Volltextzugriff (PDF)

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

Journal of clinical oncology, 1995-08, Vol.13 (8), p.1880-1892

1995

Volltextzugriff (PDF)

Association of intratumoral pharmacokinetics of fluorouracil with clinical response

The Lancet (British edition), 1994-05, Vol.343 (8907), p.1184-1187

1994

Volltextzugriff (PDF)

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer

European journal of cancer (1990), 2021-09, Vol.154, p.11-20

2021

Volltextzugriff (PDF)

Endometrial carcinoma in-vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic (MICK) apoptosis assay: Implications for endometrial cancer treatment

Gynecologic oncology, 2010-03, Vol.116 (3), p.595-595

2010

Volltextzugriff (PDF)

Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma

The Lancet (British edition), 1993-05, Vol.341 (8855), p.1242-1243

1993

Volltextzugriff (PDF)

Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer

JNCI : Journal of the National Cancer Institute, 2002-02, Vol.94 (4), p.291-297

2002

Volltextzugriff (PDF)

Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics

Clinical pharmacology and therapeutics, 2004-11, Vol.76 (5), p.508-508

2004

Volltextzugriff (PDF)

Patient Costs on Clinical Trials

JNCI : Journal of the National Cancer Institute, 2000-09, Vol.92 (17), p.1441-1442

Presant, C A

2000

Volltextzugriff (PDF)

Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes

The Lancet (British edition), 1990-06, Vol.335 (8701), p.1307-1309

1990

Volltextzugriff (PDF)

Psychosocial (PS) resilience augmenting strategies (RAS) in patients (PT) with cancer (CA) post-traumatic growth (PTG): A pilot study for personalized survivorship improvement

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e19718-e19718

2011

Volltextzugriff (PDF)

Patient (PT) participation and disaster (D) agency (AG) coordination for oncology (ONC) PT D preparedness (PREP): Analysis of the Great Southern California Shake Out (GSCSO) drill and implications for regional and national emergency (E) planning (P)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e17549-e17549

2009

Volltextzugriff (PDF)

Vitamin D (vD) deficiency (def) in breast cancer (BC) patients (pts)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.11082-11082

2007

Volltextzugriff (PDF)

Abstract P3-06-28: Use of the MiCK drug-induced apoptosis assay improves clinical outcomes in recurrent breast cancer (BRCA)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P3-P3-06-28

2012

Volltextzugriff (PDF)

Patterns of metastatic (met) disease sites in breast cancer (BrCa): Implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (TP) in met disease

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e12004-e12004

2009

Volltextzugriff (PDF)

A novel copay foundation assistance support program for patients receiving cancer therapy in cancer centers

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.6630-6630

2009

Volltextzugriff (PDF)

Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience

Journal of clinical oncology, 1986-11, Vol.4 (11), p.1658-1661

1986

Volltextzugriff (PDF)

Targeted liposomal daunorubicin (LDauno) dose escalation is feasible with filgrastim (F): Improved tumor response in colon cancer (CoC), prostate cancer (PrC), and non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2107-2107

2005

Volltextzugriff (PDF)

5-Fluorouracil revisited: A new perspective for treatment planning

Annals of oncology, 1997-02, Vol.8 (2), p.203-204

1997

Volltextzugriff (PDF)

Re-evaluation of benefits of BRCA1/2 testing

Journal of clinical oncology, 1999-06, Vol.17 (6), p.1962-1962

1999

Volltextzugriff (PDF)

Patient (pt) evaluation of the Oncology Pt Emergency Network (OPEN): Implications for oncology practices

Journal of clinical oncology, 2008-05, Vol.26 (15_suppl), p.6545-6545

2008

Volltextzugriff (PDF)

The value of personalized treatment (Rx) planning (PTP): Cost savings (sav) by the Microculture Kinetic (MiCK) chemosensitivity (CS) assay, evidence from a large American self-insured company (ASIC)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e17541-e17541

2009

Volltextzugriff (PDF)

Chemosensitivity (CS) of patient (pt) breast cancer (BrCa) cells in vitro: Correlation with prior chemotherapy (CT) and implications for personalized treatment planning

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.e11563-e11563

2009

Volltextzugriff (PDF)

Monitoring effects of imatinib (Ima) plus gemcitabine (Ge) chemotherapy (CT) on functional status of tumors (T) using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and magnetic resonance spectroscopy (MRS)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.13001-13001

2007

Volltextzugriff (PDF)

Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies

NMR in biomedicine, 1998-11, Vol.11 (7), p.380-387

1998

Volltextzugriff (PDF)

1 – 25 von 173

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(143)
Mit Volltextzugriff
(131)

Publikationsform

Sprache

Englisch
(173)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Humans
(113)
Science & Technology
(102)
Life Sciences & Biomedicine
(101)
Oncology
(71)
Female
(66)
Male
(66)
Middle Aged
(57)
Adult
(44)
Aged
(42)
Biological And Medical Sciences
(41)
Medical Sciences
(41)
Chemotherapy
(32)
Pharmacology. Drug Treatments
(30)
Antineoplastic Agents
(29)
Drug Evaluation
(28)
Drug Therapy, Combination
(28)
Neoplasms - Drug Therapy
(19)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(17)
Breast Neoplasms - Drug Therapy
(14)
Clinical Trials As Topic
(13)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial

Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805

Association of intratumoral pharmacokinetics of fluorouracil with clinical response

Phase I/II trial of palbociclib, pembrolizumab and letrozole in patients with hormone receptor-positive metastatic breast cancer

Endometrial carcinoma in-vitro chemosensitivity testing of single and combination chemotherapy regimens using the novel microculture kinetic (MICK) apoptosis assay: Implications for endometrial cancer treatment

Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma

Economic Analysis of Vinorelbine Plus Cisplatin Versus Paclitaxel Plus Carboplatin for Advanced Non-Small-Cell Lung Cancer

Tumor-based pharmacokinetics has greater significance for anticancer drugs than does blood-based pharmacokinetics

Patient Costs on Clinical Trials

Preliminary report: imaging of Kaposi sarcoma and lymphoma in AIDS with indium-111-labelled liposomes

Psychosocial (PS) resilience augmenting strategies (RAS) in patients (PT) with cancer (CA) post-traumatic growth (PTG): A pilot study for personalized survivorship improvement

Patient (PT) participation and disaster (D) agency (AG) coordination for oncology (ONC) PT D preparedness (PREP): Analysis of the Great Southern California Shake Out (GSCSO) drill and implications for regional and national emergency (E) planning (P)

Vitamin D (vD) deficiency (def) in breast cancer (BC) patients (pts)

Abstract P3-06-28: Use of the MiCK drug-induced apoptosis assay improves clinical outcomes in recurrent breast cancer (BRCA)

Patterns of metastatic (met) disease sites in breast cancer (BrCa): Implications for availability of fresh tumor tissue (FTT) for personalized BrCa treatment (Rx) planning (TP) in met disease

A novel copay foundation assistance support program for patients receiving cancer therapy in cancer centers

Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience

Targeted liposomal daunorubicin (LDauno) dose escalation is feasible with filgrastim (F): Improved tumor response in colon cancer (CoC), prostate cancer (PrC), and non-small cell lung cancer (NSCLC)

5-Fluorouracil revisited: A new perspective for treatment planning

Re-evaluation of benefits of BRCA1/2 testing

Patient (pt) evaluation of the Oncology Pt Emergency Network (OPEN): Implications for oncology practices

The value of personalized treatment (Rx) planning (PTP): Cost savings (sav) by the Microculture Kinetic (MiCK) chemosensitivity (CS) assay, evidence from a large American self-insured company (ASIC)

Chemosensitivity (CS) of patient (pt) breast cancer (BrCa) cells in vitro: Correlation with prior chemotherapy (CT) and implications for personalized treatment planning

Monitoring effects of imatinib (Ima) plus gemcitabine (Ge) chemotherapy (CT) on functional status of tumors (T) using dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) and magnetic resonance spectroscopy (MRS)

Non-invasive 19F-NMRS of 5-fluorouracil in pharmacokinetics and pharmacodynamic studies

Suchergebnisse filtern